ILIβ+3953 exon 5 and IL-2-330 promoter polymorphisms in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 23, Issue 2, 2005, Pages 159-164

  Pawlik, Andrzej ^a   Kurzawski, Mateusz ^a   Florczak, Marcin ^a   Gawronska Szklarz, Barbara ^a   Herczyńska, Magdalena ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

IL 1 ; IL 2; Polymorphism; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; GENOMIC DNA; GLUCOCORTICOID; INTERLEUKIN 1BETA; INTERLEUKIN 2; METHOTREXATE; INTERLEUKIN 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE PREDISPOSITION; DISEASE SEVERITY; DNA POLYMORPHISM; ERYTHROCYTE SEDIMENTATION RATE; EXON; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RHEUMATOID ARTHRITIS; RISK FACTOR; SCORING SYSTEM; GENETIC POLYMORPHISM; GENETICS; HOSPITALIZATION; JOINT; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; ARTHRITIS, RHEUMATOID; EXONS; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-2; JOINTS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROMOTER REGIONS (GENETICS); SEVERITY OF ILLNESS INDEX;

EID: 18644373008     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. ARED WP, DAYER JM: Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-15.
2. DAYER JM: The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology 2003; 42: 3-10.
3. EMERY P, WILLIAMSON DJ, MacKAY IR: Role of cytokines in rheumatological inflammation. Concepts Immunopathol 1987; 4: 171-99.
4. POCIOT F, MOLVIG J, WOGENSEN L et al.: Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 1992; 22: 396-402.
5. HOFFMANN SC, STANLEY EM, DARRIN COX E et al.: Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation 2001; 72: 1444-50.
6. PREVOO ML, VAN 'T HOF MA, KUPER HH et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
7. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-40.
8. LAHIRI DK, BYE S, NURNBERGER JR JI: A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples that do nine other methods tested. J Biochem Biophys Meth 1992; 25: 193.
9. HODGE PJ, RIGGIO MP, KINANE DF: Failure to detect an association with IL1 genotypes in European Caucasians with generalised early onset periodontitis. J Clin Periodontol 2001, 28, 430.
10. REYNARD MP, TURNER D, NAVARRETE CV: Allele frequencies of polymorphisms of the tumour necrosis factor-alpha, interleukin-10, interferon-gamma and interleukin-2 genes in a North European Caucasoid group from the UK. Eur J Immunogenet 2000; 27: 241-9.
11. COX ED, HOFFMANN SC, DI MERCURIO BS et al.: Cytokine polymorphic analyses indicate ethnic diffrences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 2001; 72: 720-6.
12. HOFFMANN SC, STANLEY EM, COX ED et al.: Ethnicity greatly influences cytokine gene polymorphisms distribution. Am J Transpl 2002: 560-7.
13. CHAN ES, CRONSTEIN BN: Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 266-73.
14. AUPHAN N, DIDONATO JA, HELMBERG A et al.: Immunoregulatory genes and immunosuppression by glucocorticoids. Arch Toxicol Suppl 1997; 19: 87-95.
15. FURST DE: Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1992; 34: 20-5.
16. GENESTIER L, PAILLOT R, FOURNEL S et al.: Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102: 322-8.
17. CRONSTEIN BN, NAIME D, OSTAD E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
18. BOUMA MG, STAD RK, VAN DEN WILDENBERG FA et al.: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 1994; 153: 4159-68.
19. CANTAGREL A, NAVAUX F, LOUBET-LESCOULIE P et al.: Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999; 42: 1093-100.
20. BUCHS N, di GIOVINE FS, SILVESTRI T et al.: IL-1B and IL-1Ra gene polymorphisms and disease severity in rheumatoid arthritis: interaction with their plasma levels. Genes Immun 2001; 2: 222-8.
21. CVETKOVIC JT, WALLBERG-JONSSON S, STEGMAYR B et al.: Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. J Rheumatol 2002; 29: 212-9.
22. KAIJZEL EL, VAN DONGEN H, BAKKER AM et al.: Relationship of polymorphisms of the Interleukin-1 gene cluster to occurrence and severity of rheumatoid arthritis. Tissue Antigens 2002; 59: 122-6.
23. GENEVAY S, DI GIOVINE FS, PERNEGER TV et al.: Association of interleukin-4 and interleukin-1B gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum 2002; 47: 303-9.
24. HUANG CM, TSAI FJ, WU JY et al.: Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in rheumatoid arthritis. Scand J Rheumatol 2001; 30: 225-8.
25. FEDETZ M, MATESANZ F, CALIZ R et al.: Lack of association between -384 and 114 IL-2 gene polymorphisms and rheumatoid arthritis. J Rheumatol 2003; 30: 435-7.
26. GHIVIZZANI SC, KANG R, GEORGESCU HI et al.: Constitutive intra-articular expression of human IL-1 beta following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997; 159: 3604-12.
27. FLEISCHMANN RM, SCHECHTMAN J, BENNETT R et al.: Anakinra, a recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003; 48: 927-34.
28. BENDELE A, McABEE T, SENNELLO G et al.: Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
29. MORITA Y, YAMAMURA M, KAWASHIMA M et al.: Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1669-76.
30. PARTSCH G, WAGNER E, LEEB BF et al.: T cell derived cytokines in psoriatic arthritis synovial fluids. Ann Rheum Dis 1998; 57: 691-3.
31. JOHN S, MYERSCOUGH A, MARLOW A et al.: Linkage of cytokine genes to rheumatoid arthritis. Evidence of genetic heterogeneity. Ann Rheum Dis. 1998; 57: 361-5.